Basel, January 12, 2014 - Novartis announced today, that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization. Alessandro Riva, M.D., Global Head, Novartis Oncology Development and Medical Affairs, will take on the role of President of Novartis Oncology ad interim, in addition to his current role, until a successor is named in due course.
Hervé has led the Oncology business since 2010 and we thank him for his dedication and commitment to bringing breakthrough treatments to patients. We wish him all the best for his future success.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
| Central media line : +41 61 324 2200 | |
| Eric Althoff | Dermot Doherty |
e-mail: media.relations@novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.
Novartis Investor Relations
| Central phone: | +41 61 324 7944 | ||
| Samir Shah | +41 61 324 7944 | North America: | |
| Pierre-Michel Bringer | +41 61 324 1065 | Stephen Rubino | +1 862 778 8301 |
| Thomas Hungerbuehler | +41 61 324 8425 | Jill Pozarek | +1 212 830 2445 |
| Isabella Zinck | +41 61 324 7188 | Susan Donofrio | +1 862 778 9257 |
| e-mail: investor.relations@novartis.com | e-mail: investor.relations@novartis.com | ||
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
HUG#1754133